DCVC, a deep tech venture capital, and a16z, a private American venture capital firm, led a $22m Series A round in Valar Labs, a biotechnology company. “We see Valar as a leader in an emerging group of TechMed startups that harness AI and the power of data to augment physicians’ capabilities. Histology has always been one of the keys to diagnosing cancer, but Valar Labs is showing that there are unexpected depths in the digital slides pathologists review every day. And bladder cancer is only the beginning: we can’t wait to see where they take the technology next," James Hardiman, DCVC General Partner.